LAVA Therapeutics N.V. (LVTX)
NASDAQ: LVTX · Real-Time Price · USD
1.480
-0.040 (-2.63%)
Nov 21, 2024, 4:00 PM EST - Market closed
LAVA Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Jan '20 Jan 1, 2020 |
| Revenue | 7.4 | 6.77 | 19.39 | 5.35 | 3.75 | - |
| Revenue Growth (YoY) | -69.51% | -65.09% | 262.45% | 42.78% | - | - |
| Cost of Revenue | 0.16 | 3.48 | - | - | 15.7 | 8.35 |
| Gross Profit | 7.23 | 3.29 | 19.39 | 5.35 | -11.95 | -8.35 |
| Selling, General & Admin | 11.1 | 12.73 | 14.12 | 12.02 | 2.72 | 1.24 |
| Research & Development | 23.62 | 33.81 | 40.11 | 36.95 | - | - |
| Operating Expenses | 34.72 | 46.54 | 54.23 | 48.96 | 2.72 | 1.24 |
| Operating Income | -27.48 | -43.25 | -34.84 | -43.61 | -14.67 | -9.58 |
| Interest Expense | - | - | - | -0.63 | -0.34 | -0.09 |
| Interest & Investment Income | 3.28 | 2.97 | 0.26 | - | - | - |
| Currency Exchange Gain (Loss) | 0.29 | -1.41 | 2.92 | 2.04 | -0.87 | -0.02 |
| Pretax Income | -23.92 | -41.7 | -31.66 | -42.2 | -15.88 | -9.69 |
| Income Tax Expense | 0.27 | 0.28 | 0.25 | 0.16 | 0.04 | - |
| Net Income | -24.18 | -41.97 | -31.91 | -42.36 | -15.93 | -9.69 |
| Net Income to Common | -24.18 | -41.97 | -31.91 | -42.36 | -15.93 | -9.69 |
| Shares Outstanding (Basic) | 27 | 27 | 26 | 20 | 0 | 0 |
| Shares Outstanding (Diluted) | 27 | 27 | 26 | 20 | 0 | 0 |
| Shares Change (YoY) | 3.10% | 3.12% | 31.21% | 4850.36% | -10.81% | - |
| EPS (Basic) | -0.90 | -1.57 | -1.23 | -2.14 | -39.90 | -21.65 |
| EPS (Diluted) | -0.90 | -1.57 | -1.23 | -2.14 | -39.90 | -21.65 |
| Free Cash Flow | -27.09 | -39.7 | 3.46 | -29.41 | -9.81 | -9.38 |
| Free Cash Flow Per Share | -1.00 | -1.49 | 0.13 | -1.49 | -24.58 | -20.95 |
| Gross Margin | 97.78% | 48.56% | 100.00% | 100.00% | - | - |
| Operating Margin | -371.48% | -638.99% | -179.66% | -815.20% | -391.59% | - |
| Profit Margin | -326.89% | -620.09% | -164.55% | -791.68% | -425.06% | - |
| Free Cash Flow Margin | -366.14% | -586.53% | 17.82% | -549.74% | -261.78% | - |
| EBITDA | -26.88 | -42.64 | -34.33 | -43.28 | -14.46 | -9.48 |
| EBITDA Margin | - | - | -177.06% | - | - | - |
| D&A For EBITDA | 0.6 | 0.62 | 0.5 | 0.33 | 0.21 | 0.1 |
| EBIT | -27.48 | -43.25 | -34.84 | -43.61 | -14.67 | -9.58 |
| EBIT Margin | - | - | -179.66% | - | - | - |
| Revenue as Reported | - | - | - | - | 3.75 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.